P21-Activated kinase 4 promotes prostate cancer progression through CREB

Oncogene

Volumn 32, Issue 19, 2013, Pages 2475-2482

  Park, M H ^a   Lee, H S ^b   Lee, C S ^a   You, S T ^a   Kim, D J ^a   Park, B H ^b   Kang, M J ^b   Heo, W D ^c   Shin, E Y ^a   Schwartz, M A ^d   Kim, E G ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemoresistance; CREB; neuroendocrine differentiation; p21 activated kinase 4; prostate cancer; protein kinase A

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN A1; DOCETAXEL; DOXORUBICIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; P21 ACTIVATED KINASE 4; PACLITAXEL; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE COMPLEX; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MOUSE; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; TISSUE DIFFERENTIATION; TUMOR XENOGRAFT;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CREB-BINDING PROTEIN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; P21-ACTIVATED KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS;

EID: 84877633978     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.255     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010CA Cancer J Clin 2010; 60: 277-300.
2. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. New Engl J Med 2004; 351: 1488-1490.
3. Donkena KV, Yuan H, Young CY. Recent advances in understanding hormonal therapy resistant prostate cancer. Curr Cancer Drug Targets 2010; 10: 402-410.
4. Jaffer ZM, Chernoff J. p21-activated kinases: three more join the Pak. Int J Biochem Cell Biol 2002; 34: 713-717.
5. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem 2003; 72: 743-781.
6. Morreale A, Venkatesan M, Mott HR, Owen D, Nietlispach D, Lowe PN et al. Structure of Cdc42 bound to the GTPase binding domain of PAK. Nat Struct Biol 2000; 7: 384-388.
7. Lei M, Lu W, Meng W, Parrini MC, Eck MJ, Mayer BJ et al. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 2000; 102: 387-397.
8. Qu J, Cammarano MS, Shi Q, Ha KC, de Lanerolle P, Minden A. Activated PAK4 regulates cell adhesion and anchorage-independent growth. Mol Cell Biol 2001; 21: 3523-3533.
9. Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X, Lee HJ et al. The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res 2008; 6: 1215-1224.
10. Eswaran J, Soundararajan M, Knapp S. Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev 2009; 28: 209-217.
11. Wells CM, Jones GE. The emerging importance of group II PAKs. Biochemical J 2010; 425: 465-473.
12. Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR et al. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem 2002; 277: 550-558.
13. Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY et al. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci USA 2010; 107: 18622-18627.
14. Wells CM, Whale AD, Parsons M, Masters JR, Jones GE. PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J Cell Sci 2010; 123: 1663-1673.
15. Eswaran J, Lee WH, Debreczeni JE, Filippakopoulos P, Turnbull A, Fedorov O et al. Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 2007; 15: 201-213.
16. Lee KH, Lee S, Lee WY, Yang HW, Heo WD. Visualizing dynamic interaction between calmodulin and calmodulin-related kinases via a monitoring method in live mammalian cells. Proc Natl Acad Sci USA 2010; 107: 3412-3417.
17. Bagchi G, Wu J, French J, Kim J, Moniri NH, Daaka Y. Androgens transduce the G alphas-mediated activation of protein kinase A in prostate cells. Cancer Res 2008; 68: 3225-3231.
18. Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 1989; 59: 675-680.
19. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994; 91: 5330-5334.
20. Cox ME, Deeble PD, Bissonette EA, Parsons SJ. Activated 3', 5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 2000; 275: 13812-13818.
21. Wilson BE, Mochon E, Boxer LM. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996; 16: 5546-5556.
22. Wells CM, Abo A, Ridley AJ. PAK4 is activated via PI3K in HGF-stimulated epithelial cells. J Cell Sci 2002; 115: 3947-3956.
23. Paliouras GN, Naujokas MA, Park M. Pak4 a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor. Mol Cell Biol 2009; 29: 3018-3032.
24. Higuchi M, Onishi K, Kikuchi C, Gotoh Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat Cell Biol 2008; 10: 1356-1364.
25. Baldassa S, Calogero AM, Colombo G, Zippel R, Gnesutta N. N-terminal interaction domain implicates PAK4 in translational regulation and reveals novel cellular localization signals. J Cell Physiol 2010; 224: 722-733.
26. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 1995; 68: 821-861.
27. Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM. Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets 2010; 10: 384-391.
28. Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci USA 2010; 107: 9446-9451.
29. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endoc Relat Cancer 2007; 14: 531-547.
30. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162: 1800-1805.
31. Ahmed T, Shea K, Masters JR, Jones GE, Wells CM. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal 2008; 20: 1320-1328.
32. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
33. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438-4445.